Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.61 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | CBFB | Q13951 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121710 | 0.87 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CBPIK3CAMETAP2 | |
| SCHEMBL28565071 | 0.84 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CBPIK3CAMETAP2 | |
| SCHEMBL20061345 | 0.84 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CBPIK3CAMETAP2 | |
| SCHEMBL2718717 | 0.84 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3CBPIK3CAMETAP2 | |
| SCHEMBL3781566 | 0.83 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL2716698 | 0.79 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CBPIK3CAMETAP2 | |
| SCHEMBL3777170 | 0.78 | PIK3CD (0.55) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL6127154 | 0.78 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3CBPIK3CAMETAP2 | |
| SCHEMBL2720600 | 0.78 | PIK3CD (0.65) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL2731651 | 0.77 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2445900-B1 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | AMGEN INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2445900-B1 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | AMGEN INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2445900-A2 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 15/4885PIK3CG 53/4885PIK3CB 35/4885 |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3CG 54/4885PIK3CB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.